AD
MCID: ALZ034
MIFTS: 86

Alzheimer Disease (AD)

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Alzheimer Disease

MalaCards integrated aliases for Alzheimer Disease:

Name: Alzheimer Disease 57 12 24 53 25 75 37 29 44 38 40
Alzheimer's Disease 38 12 76 25 54 29 6 43 3 15 63 73
Presenile and Senile Dementia 57 25 75
Ad 57 25 75
Alzheimer Disease, Late-Onset, Susceptibility to 57 6
Alzheimer Disease, Susceptibility to 57 6
Alzheimer Disease 1, Familial 57 13
Familial Alzheimer Disease 25 73
Alzheimer Disease, Early-Onset, with Cerebral Amyloid Angiopathy 6
Early-Onset Alzheimer Disease with Cerebral Amyloid Angiopathy 75
Primary Senile Degenerative Dementia 25
Autosomal Dominant Alzheimer Disease 75
Dementia Due to Alzheimer's Disease 73
Alzheimer's Disease Pathway Kegg 73
Alzheimer Disease, Late-Onset 57
Alzheimer Disease Type 1 73
Alzheimer-Type Dementia 25
Alzheimers Dementia 12
Alzheimer Disease 1 75
Alzheimer Sclerosis 25
Alzheimer Dementia 25
Alzheimer Syndrome 25
Alzheimers Disease 55
Sdat 25
Ad1 75
Dat 25

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
genetic heterogeneity


HPO:

32
alzheimer disease:
Inheritance heterogeneous autosomal dominant inheritance


Classifications:



Summaries for Alzheimer Disease

NINDS : 54 Alzheimer's disease (AD) is an age-related, non-reversible brain disorder that develops over a period of years. Initially, people experience memory loss and confusion, which may be mistaken for the kinds of memory changes that are sometimes associated with normal aging. However, the symptoms of AD gradually lead to behavior and personality changes, a decline in cognitive abilities such as decision-making and language skills, and problems recognizing family and friends. AD ultimately leads to a severe loss of mental function. These losses are related to the worsening breakdown of the connections between certain neurons in the brain and their eventual death. AD is one of a group of disorders called dementias that are characterized by cognitive and behavioral problems. It is the most common cause of dementia among people age 65 and older. There are three major hallmarks in the brain that are associated with the disease processes of AD. Amyloid plaques, which are made up of fragments of a protein called beta-amyloid peptide mixed with a collection of additional proteins, remnants of neurons, and bits and pieces of other nerve cells. Neurofibrillary tangles (NFTs), found inside neurons, are abnormal collections of a protein called tau. Normal tau is required for healthy neurons. However, in AD, tau clumps together. As a result, neurons fail to function normally and eventually die. Loss of connections between neurons responsible for memory and learning. Neurons can't survive when they lose their connections to other neurons. As neurons die throughout the brain, the affected regions begin to atrophy, or shrink. By the final stage of AD, damage is widespread and brain tissue has shrunk significantly.

MalaCards based summary : Alzheimer Disease, also known as alzheimer's disease, is related to alzheimer disease 2 and alzheimer disease mitochondrial, and has symptoms including seizures, tremor and angina pectoris. An important gene associated with Alzheimer Disease is APP (Amyloid Beta Precursor Protein), and among its related pathways/superpathways are Alzheimer disease and MicroRNAs in cancer. The drugs Galantamine and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include Brain and Blood, and related phenotypes are dementia and parkinsonism

Disease Ontology : 12 A tauopathy that is characterized by memory lapses, confusion, emotional instability and progressive loss of mental ability and results in progressive memory loss, impaired thinking, disorientation, and changes in personality and mood starting and leads in advanced cases to a profound decline in cognitive and physical functioning and is marked histologically by the degeneration of brain neurons especially in the cerebral cortex and by the presence of neurofibrillary tangles and plaques containing beta-amyloid.

Genetics Home Reference : 25 Alzheimer disease is a degenerative disease of the brain that causes dementia, which is a gradual loss of memory, judgment, and ability to function. This disorder usually appears in people older than age 65, but less common forms of the disease appear earlier in adulthood.

NIH Rare Diseases : 53 Alzheimer disease (AD) is a degenerative disease of the brain that causes gradual loss of memory, judgment, and the ability to function socially. Alzheimer disease currently affects about 5 million people. About 75 percent of Alzheimer disease cases are classified as sporadic, which means they occur in people with no history of the disorder in their family. Although the cause of these cases is unknown, genetic changes are likely to play a role. Virtually all sporadic cases of Alzheimer disease begin after age 65, and the risk of developing this condition increases as a person gets older. AD can be subdivided into two groups based on the age of onset: (1) Early-onset (1%-6% of the cases) which start in people younger than 60- 65 years of age (2) Late-onset, which starts in people older than 65 years old. In about 25% of cases, AD is familial (2 or more people in a family have AD). For more information, please visit GARD's familial Alzheimer disease Web page.

OMIM : 57 Alzheimer disease is the most common form of progressive dementia in the elderly. It is a neurodegenerative disorder characterized by the neuropathologic findings of intracellular neurofibrillary tangles (NFT) and extracellular amyloid plaques that accumulate in vulnerable brain regions (Sennvik et al., 2000). Terry and Davies (1980) pointed out that the 'presenile' form, with onset before age 65, is identical to the most common form of late-onset or 'senile' dementia, and suggested the term 'senile dementia of the Alzheimer type' (SDAT). Haines (1991) reviewed the genetics of AD. Selkoe (1996) reviewed the pathophysiology, chromosomal loci, and pathogenetic mechanisms of Alzheimer disease. Theuns and Van Broeckhoven (2000) reviewed the transcriptional regulation of the genes involved in Alzheimer disease. (104300)

MedlinePlus : 43 Alzheimer's disease (AD) is the most common form of dementia among older people. Dementia is a brain disorder that seriously affects a person's ability to carry out daily activities. AD begins slowly. It first involves the parts of the brain that control thought, memory and language. People with AD may have trouble remembering things that happened recently or names of people they know. A related problem, mild cognitive impairment (MCI), causes more memory problems than normal for people of the same age. Many, but not all, people with MCI will develop AD. In AD, over time, symptoms get worse. People may not recognize family members. They may have trouble speaking, reading or writing. They may forget how to brush their teeth or comb their hair. Later on, they may become anxious or aggressive, or wander away from home. Eventually, they need total care. This can cause great stress for family members who must care for them. AD usually begins after age 60. The risk goes up as you get older. Your risk is also higher if a family member has had the disease. No treatment can stop the disease. However, some drugs may help keep symptoms from getting worse for a limited time. NIH: National Institute on Aging

CDC : 3 Although scientists are learning more every day, right now, they still do not know what causes Alzheimer’s disease.

UniProtKB/Swiss-Prot : 75 Alzheimer disease: Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death. Alzheimer disease 1: A familial early-onset form of Alzheimer disease. It can be associated with cerebral amyloid angiopathy. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death.

PubMed Health : 63 About alzheimer's disease: Alzheimer's disease is the most common cause of dementia. It takes its name from the psychiatrist Alois Alzheimer, who in the early twentieth century was the first person to describe the disease. Over time, people who have Alzheimer’s lose their memory and ability to concentrate. Orientation in space and time become increasingly difficult, and it is also harder for them to manage on their own in everyday life. Those affected need more support as the disease progresses.The course of Alzheimer’s can be positively influenced by a number of different medications and non-drug treatments – but it is not possible to cure the disease or to keep it from progressing. This makes it even more critical for people with Alzheimer’s to receive good care and support: They need loving and stable relationships and a tolerant environment. Many family members need help and assistance too.There are other possible causes of dementia besides Alzheimer’s disease. These include problems with the flow of blood in the brain (vascular dementia). Some people – particularly older people – have both Alzheimer’s and vascular dementia. Medical conditions such as Parkinson’s disease, brain injuries or tumors can also cause dementia. Long-term heavy alcohol consumption may lead to dementia too.There are similarities, but also differences, between the different forms of dementia: The symptoms, the course the disease takes, and the treatment options can all vary. This overview is only about Alzheimer’s.

Wikipedia : 76 Alzheimer''s disease (AD), also referred to simply as Alzheimer''s, is a chronic neurodegenerative... more...

GeneReviews: NBK1161

Related Diseases for Alzheimer Disease

Diseases in the Alzheimer Disease family:

Alzheimer Disease 2 Alzheimer Disease 16
Alzheimer Disease 5 Alzheimer Disease 6
Alzheimer Disease 7 Alzheimer Disease 4
Alzheimer Disease 8 Alzheimer Disease 3
Alzheimer Disease 9 Alzheimer Disease 10
Alzheimer Disease 11 Alzheimer Disease 12
Alzheimer Disease 13 Alzheimer Disease 14
Alzheimer Disease 15 Alzheimer Disease 17
Alzheimer Disease 18 Alzheimer Disease 19
Alzheimer's Disease 1 Early-Onset, Autosomal Dominant Alzheimer Disease

Diseases related to Alzheimer Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 899)
# Related Disease Score Top Affiliating Genes
1 alzheimer disease 2 34.8 PLAU NOS3 APP
2 alzheimer disease mitochondrial 34.0 MT-ND1 APP
3 diabetes mellitus 30.6 NOS3 MT-ND1 MIR34A HFE CDKN2B-AS1
4 inclusion body myositis 30.4 MIR34A BACE1-AS BACE1 APP
5 ovarian cancer 30.1 PLAU MIR29A MIR146A MIR106B CDKN2B-AS1 BCYRN1
6 lung cancer 30.0 PLAU MIR34A MIR29A MIR146A MIR107 CDKN2B-AS1
7 colorectal cancer 29.9 PLAU MIR34A MIR328 MIR29A MIR107 MIR106B
8 leukemia, chronic lymphocytic 2 29.9 MIR34A MIR29A MIR107 MIR106B
9 hepatocellular carcinoma 29.8 MIR34A MIR29A MIR146A MIR107 MIR106B HFE
10 leukemia, acute myeloid 29.8 MPO MIR328 MIR146A CDKN2B-AS1
11 esophageal cancer 29.7 PLAU MIR34A MIR107 CDKN2B-AS1 BCYRN1
12 pancreatic cancer 29.7 PLAU MIR34A MIR146A MIR107 CDKN2B-AS1
13 early-onset, autosomal dominant alzheimer disease 12.7
14 alzheimer disease 6 12.6
15 alzheimer disease 19 12.6
16 alzheimer disease 3 12.6
17 alzheimer disease 4 12.5
18 alzheimer disease 18 12.5
19 alzheimer disease 9 12.4
20 alzheimer disease 5 12.3
21 alzheimer disease 7 12.3
22 alzheimer disease 8 12.3
23 alzheimer disease 12 12.3
24 alzheimer disease 10 12.3
25 alzheimer disease 11 12.3
26 alzheimer disease 15 12.3
27 alzheimer disease 13 12.2
28 alzheimer disease 14 12.2
29 alzheimer disease 17 12.2
30 alzheimer disease 16 12.1
31 dopa-responsive dystonia; segawa syndrome ad 12.1
32 alzheimer disease without neurofibrillary tangles 12.0
33 alzheimer disease, familial early-onset, with coexisting amyloid and prion pathology 12.0
34 hyper-ige recurrent infection syndrome, autosomal dominant 11.9
35 dementia, lewy body 11.8
36 immunodeficiency 27b 11.7
37 myopathy, centronuclear, 1 11.7
38 renal tubular acidosis, distal, autosomal dominant 11.7
39 hypocalcemia, autosomal dominant 1 11.6
40 supranuclear palsy, progressive, 1 11.4
41 alzheimer's disease 1 11.4
42 posterior cortical atrophy 11.4
43 down syndrome 11.3
44 parkinson disease, late-onset 11.3
45 schizophrenia 11.2
46 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 11.2
47 cerebral amyloid angiopathy, app-related 11.2
48 dermatitis, atopic 11.2
49 keratomalacia 11.2
50 eosinophilic granulomatosis with polyangiitis 11.2

Comorbidity relations with Alzheimer Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 55)


Active Peptic Ulcer Disease Acute Conjunctivitis
Acute Cystitis Acute Kidney Failure
Amnestic Disorder Bronchitis
Bronchopneumonia Cerebral Atherosclerosis
Cerebral Degeneration Cerebrovascular Disease
Communicating Hydrocephalus Conduct Disorder
Conjunctivitis Cystitis
Decubitus Ulcer Deficiency Anemia
Delusional Disorder Dental Caries
Dermatomycosis Encephalopathy
Fecal Incontinence Folic Acid Deficiency Anemia
Generalized Atherosclerosis Grn-Related Frontotemporal Dementia
Heart Disease Hypoglycemia
Hypothyroidism Intermittent Explosive Disorder
Intestinal Volvulus Iron Deficiency Anemia
Kidney Disease Kohlschutter-Tonz Syndrome
Latent Syphilis Major Depressive Disorder
Marasmus Neurogenic Bladder
Nutritional Deficiency Disease Obstructive Hydrocephalus
Ocular Motor Apraxia Oral Candidiasis
Osteoporosis Paralytic Ileus
Paranoid Schizophrenia Parkinson Disease, Late-Onset
Pernicious Anemia Personality Disorder
Protein-Energy Malnutrition Pyelonephritis
Scabies Schizophrenia

Graphical network of the top 20 diseases related to Alzheimer Disease:



Diseases related to Alzheimer Disease

Symptoms & Phenotypes for Alzheimer Disease

Symptoms via clinical synopsis from OMIM:

57
Neurologic Central Nervous System:
parkinsonism
presenile and senile dementia
long tract signs
neurofibrillary tangles composed of disordered microtubules


Clinical features from OMIM:

104300

Human phenotypes related to Alzheimer Disease:

32 (show all 7)
# Description HPO Frequency HPO Source Accession
1 dementia 32 HP:0000726
2 parkinsonism 32 HP:0001300
3 neurofibrillary tangles 32 HP:0002185
4 senile plaques 32 HP:0100256
5 alzheimer disease 32 HP:0002511
6 long-tract signs 32 HP:0002423
7 decreased level of gaba in serum 32 HP:0410054

UMLS symptoms related to Alzheimer Disease:


seizures, tremor, angina pectoris, myoclonus, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, equilibration disorder, sleeplessness

Drugs & Therapeutics for Alzheimer Disease

PubMedHealth treatment related to Alzheimer Disease: 63

People who have Alzheimer’s need long-term help and treatment. Depending on their needs, their life situation and the stage of disease, a whole team of people may be involved in providing care. These could include trained doctors, psychologists, nurses and social workers, as well as volunteers. Both treatment with medications and non-drug interventions aim toincrease quality of life,keep the ability to do everyday tasks and stay independent for as long as possible,reduce mental health problems, andhelp family members to cope better.The most common medications used to treat Alzheimer’s disease include cholinesterase inhibitors, memantine and extracts from the leaves of the Ginkgo biloba tree.Examples of non-drug treatments include memory and orientation training, doing everyday activities as a group, or art therapy, aromatherapy, and animal-assisted or music therapy. Physical activities and massages can help too. Caregiver training for family members is important too.

Drugs for Alzheimer Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 714)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Galantamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 357-70-0 9651
2
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 120014-06-4 3152
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
4
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
5 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 19982-08-2 4054
7
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 106266-06-2 5073
8
Rivastigmine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 123441-03-2 77991
9
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59729-33-8 2771
10
Huperzine A Approved, Experimental Phase 4,Phase 2,Phase 3 102518-79-6
11
Levodopa Approved Phase 4,Phase 1,Phase 2,Not Applicable 59-92-7 6047
12
Warfarin Approved Phase 4,Phase 3,Phase 1 81-81-2 6691 54678486
13
Rivaroxaban Approved Phase 4 366789-02-8
14
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 50-78-2 2244
15
Ticagrelor Approved Phase 4,Phase 3 274693-27-5 9871419
16
Clopidogrel Approved Phase 4,Phase 3,Not Applicable 113665-84-2, 120202-66-6 60606
17
Metformin Approved Phase 4,Phase 2 657-24-9 14219 4091
18
Amlodipine Approved Phase 4,Phase 2,Phase 3 88150-42-9 2162
19
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-28-2 5757
20
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 28014-46-2
21
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 71-58-9
22
Progesterone Approved, Vet_approved Phase 4,Phase 2,Phase 3 57-83-0 5994
23 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 979-32-8
24
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 2078-54-8 4943
25
Nicotine Approved Phase 4,Phase 2,Phase 1,Not Applicable 54-11-5 942 89594
26
Ibuprofen Approved Phase 4,Phase 3,Phase 1,Early Phase 1 15687-27-1 3672
27
Lithium carbonate Approved Phase 4,Phase 2,Phase 1,Not Applicable 554-13-2
28
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2,Not Applicable 13422-51-0 11953898 44475014
29
Methylcobalamin Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 13422-55-4
30
Isoflurane Approved, Vet_approved Phase 4,Phase 1,Not Applicable 26675-46-7 3763
31
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
32
Gabapentin Approved, Investigational Phase 4,Not Applicable 60142-96-3 3446
33
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
34
Sodium oxybate Approved Phase 4 502-85-2 5360545
35
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
36
Dextromethorphan Approved Phase 4,Phase 3,Phase 2,Phase 1 125-71-3 5360696 5362449
37
Quinidine Approved, Investigational Phase 4,Phase 3,Phase 2 56-54-2 441074
38
Dextroamphetamine Approved, Illicit Phase 4,Phase 3 51-64-9 5826
39
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 113-45-1 4158
40
Acetylcarnitine Approved, Investigational Phase 4,Phase 2 3040-38-8 1
41
Haloperidol Approved Phase 4,Phase 3 52-86-8 3559
42
Cilostazol Approved, Investigational Phase 4,Phase 2,Phase 3 73963-72-1 2754
43
Ramipril Approved Phase 4 87333-19-5 5362129
44
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
45
Valproic Acid Approved, Investigational Phase 4,Phase 3,Early Phase 1 99-66-1 3121
46
Sertraline Approved Phase 4,Phase 2,Phase 3,Not Applicable 79617-96-2 68617
47
Atropine Approved, Vet_approved Phase 4 51-55-8, 5908-99-6 174174
48
Pravastatin Approved Phase 4 81093-37-0 54687
49
Norepinephrine Approved Phase 4,Phase 1,Not Applicable 51-41-2 439260
50
Olanzapine Approved, Investigational Phase 4,Not Applicable 132539-06-1 4585

Interventional clinical trials:

(show top 50) (show all 2610)
# Name Status NCT ID Phase Drugs
1 Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®) Unknown status NCT00523666 Phase 4 Galantamine (Reminyl®);Placebo/Galantamine (Reminyl®)
2 Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease Unknown status NCT01849042 Phase 4 Ebixa;donepezil
3 Donepezil and Memantine in Moderate to Severe Alzheimer's Disease Unknown status NCT00866060 Phase 4 Memantine;Donepezil;Placebo donepezil;Placebo memantine
4 Effect of Cognitive Intervention in Alzheimer's Disease (AD) on Functional Cortical Networks in fMRI Unknown status NCT01329601 Phase 4
5 The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer's Disease and Behavioural and Psychological Symptoms of Dementia (BPSD) Unknown status NCT00626613 Phase 4 Risperdal,reminyl
6 Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD Unknown status NCT02444637 Phase 4 Rivastigmine
7 Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
8 Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging Unknown status NCT02931136 Phase 4 Huperzine A;Placebo
9 CALM-AD Unknown status NCT00142324 Phase 4 Donepezil
10 A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer Patients Unknown status NCT02648906 Phase 4 Choline alfoscerate;Placebo
11 Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment Unknown status NCT00306124 Phase 4 Levodopa
12 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
13 Memantine for Agitation in Dementia Unknown status NCT00371059 Phase 4 Memantine;Placebo
14 Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia Unknown status NCT01012830 Phase 4 Huperzine A
15 Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study Unknown status NCT02409238 Phase 4 Metformin
16 Gastrodin Prevents Cognitive Decline Related to Cardiopulmonary Bypass Unknown status NCT00297245 Phase 4 cognitive function
17 Memantine for Post-Operative Pain Control Unknown status NCT01041313 Phase 4 Memantine;Placebo
18 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity Unknown status NCT01567774 Phase 4 Atorvastatin;Rosuvastatin
19 Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment:Pilot Study Unknown status NCT02190019 Phase 4
20 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
21 Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT) Withdrawn NCT01822951 Phase 4 Cerebrolysin;Donepezil
22 Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors Completed NCT01529619 Phase 4 Rivastigmine transdermal patch
23 Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care Active, not recruiting NCT01993836 Phase 4 Total intravenous anesthesia with propofol;General anesthesia with isoflurane
24 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients Completed NCT01948791 Phase 4 ENA713
25 NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients. Completed NCT02703636 Phase 4 Rivastigmine Patch
26 Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease Recruiting NCT03703856 Phase 4 Memantine;Placebo
27 Memantine Treatment in Alzheimer's Disease Patients Not yet recruiting NCT03168997 Phase 4 Memantine Hydrochloride
28 Trial of Carvedilol in Alzheimer's Disease Completed NCT01354444 Phase 4 Carvedilol;Placebo
29 The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease Completed NCT00381381 Phase 4 Donepezil
30 Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease Completed NCT02097056 Phase 4 Donepezil HCL
31 Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease. Completed NCT00731224 Phase 4 Rivastigmine transdermal patch
32 The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease Completed NCT01054976 Phase 4 Galantamine
33 Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease Active, not recruiting NCT02787746 Phase 4 Donepezil
34 Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 Completed NCT00948766 Phase 4 Rivastigmine 4.6 mg/24 h (5 cm^2);Rivastigmine 9.5 mg/24 h (10 cm^2);Rivastigmine 13.3 mg/24 h (15 cm^2);Placebo
35 Escitalopram for the Treatment of Depression in Alzheimer's Disease Completed NCT01841125 Phase 4 escitalopram;Placebo
36 Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training Completed NCT00120874 Phase 4 Memantine
37 Double Blind Study of Trp01 in Patients With Alzheimer's Disease Completed NCT00202124 Phase 4 Tryptophan
38 Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease Completed NCT00476008 Phase 4 Memantine;Placebo
39 Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease Completed NCT00561392 Phase 4 Rivastigmine 5 and 10 cm^2 patch
40 Neural Correlates In Mild Alzheimer's Disease Completed NCT00477659 Phase 4 donepezil HCl (Aricept)
41 A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease Completed NCT01047579 Phase 4 Rivastigmine transdermal
42 Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease Completed NCT00551161 Phase 4 memantine
43 Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients Terminated NCT00369603 Phase 4 Razadyne ER;Aricept
44 A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease Completed NCT00035204 Phase 4 galantamine
45 Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease Recruiting NCT03082755 Phase 4 Gabapentin Enacarbil;Placebo Oral Tablet
46 Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease Withdrawn NCT00711204 Phase 4 Donepezil Hydrochloride (Aricept)
47 Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease Completed NCT00469456 Phase 4 Memantine;placebo
48 A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA) Completed NCT00622713 Phase 4 Rivastigmine transdermal patch
49 Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease Completed NCT00104442 Phase 4 Rivastigmine
50 Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE) Completed NCT00867828 Phase 4

Search NIH Clinical Center for Alzheimer Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Alzheimer Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Alzheimer Disease:
NEUROSTEM�-AD, human mesenchymal stem cells for the treatment of Alzheimer's disease
Embryonic/Adult Cultured Cells Related to Alzheimer Disease:
Umbilical cord blood-derived mesenchymal stem/progenitor cells PMIDs: 23293711 22015609

Cochrane evidence based reviews: alzheimer disease

Genetic Tests for Alzheimer Disease

Genetic tests related to Alzheimer Disease:

# Genetic test Affiliating Genes
1 Alzheimer's Disease 29 A2M APP HFE MPO NOS3 PLAU
2 Alzheimer Disease 29

Anatomical Context for Alzheimer Disease

MalaCards organs/tissues related to Alzheimer Disease:

41
Brain, Testes, Cortex, Endothelial, Temporal Lobe, Heart, Eye
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Alzheimer Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Brain Forebrain White Matter Fibrous Astrocyte Cells Affected by disease, potential therapeutic candidate
2 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
3 Brain Forebrain White Matter Myelinating Oligodendrocyte Cells Affected by disease
4 Brain Neocortex Protoplasmic Astrocyte Cells Affected by disease, potential therapeutic candidate
5 Brain Hippocampus Affected by disease

Publications for Alzheimer Disease

Articles related to Alzheimer Disease:

(show top 50) (show all 15483)
# Title Authors Year
1
Dendritic spine remodeling accompanies Alzheimer's disease pathology and genetic susceptibility in cognitively normal aging. ( 30339964 )
2019
2
Exosomes and microRNAs: New potential therapeutic candidates in Alzheimer disease therapy. ( 30191975 )
2019
3
Assessing disease-modifying effects of norepinephrine in Down syndrome and Alzheimer's disease. ( 29102776 )
2019
4
Protective and reversal actions of a novel peptidomimetic against a pivotal toxin implicated in Alzheimer's disease. ( 30551355 )
2019
5
Amyloid β and tau are involved in sleep disorder in Alzheimer's disease by orexin A and adenosine A(1) receptor. ( 30365112 )
2019
6
The opioid system in stress-induced memory disorders: From basic mechanisms to clinical implications in post-traumatic stress disorder and Alzheimer's disease. ( 30118823 )
2019
7
Impaired chemoreflex correlates with decreased c-Fos in respiratory brainstem centers of the streptozotocin-induced Alzheimer's disease rat model. ( 30359566 )
2019
8
MicroRNA-98 reduces amyloid β-protein production and improves oxidative stress and mitochondrial dysfunction through the Notch signaling pathway via HEY2 in Alzheimer's disease mice. ( 30365070 )
2019
9
Role of intracellular Ca2+ stores for an impairment of visual processing in a mouse model of Alzheimer's disease. ( 30366066 )
2019
10
Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology. ( 30317034 )
2019
11
"Microchip Electrophoresis," with Respect to "Profiling of Aβ Peptides in the Cerebrospinal Fluid of Patients with Alzheimer's Disease". ( 30426429 )
2019
12
Synthesis and biological assessment of KojoTacrines as new agents for Alzheimer's disease therapy. ( 30482062 )
2019
13
Multitarget therapeutic strategies for Alzheimer's disease. ( 30539809 )
2019
14
An innovative approach for the treatment of Alzheimer's disease: the role of peroxisome proliferator-activated receptors and their ligands in development of alternative therapeutic interventions. ( 30531068 )
2019
15
MicroRNAs as diagnostic and therapeutic tools for Alzheimer's disease: advances and limitations. ( 30531004 )
2019
16
Impaired perceptual integration and memory for unitized representations are associated with perirhinal cortex atrophy in Alzheimer's disease. ( 30342274 )
2019
17
Neuroprotective action of diazepam at very low and moderate doses in Alzheimer's disease model rats. ( 30408486 )
2019
18
The Importance of Keeping Your Brain's Pipes Clean: The role of Meningeal Lymphatics in Ageing and Alzheimer's Disease. ( 30395333 )
2019
19
The GSK3β inhibitor, TDZD-8, rescues cognition in a zebrafish model of okadaic acid-induced Alzheimer's disease. ( 30392874 )
2019
20
Mulberry Diels-Alder-type adducts from Morus alba as multi-targeted agents for Alzheimer's disease. ( 30390605 )
2019
21
A novel therapeutic potential of cysteinyl leukotrienes and their receptors modulation in the neurological complications associated with Alzheimer's disease. ( 30389631 )
2019
22
OAB-14, a bexarotene derivative, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice. ( 30389579 )
2019
23
The effect of different alcohols on the Asp23-Lys28 and Asp23-Ala42 salt bridges of the most effective peptide in Alzheimer's disease: Molecular dynamics viewpoints. ( 30388694 )
2019
24
Synthesis, biological evaluation and molecular dynamic simulations of novel Benzofuran-tetrazole derivatives as potential agents against Alzheimer's disease. ( 30455151 )
2019
25
Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer's disease. ( 30314815 )
2019
26
EIF2AK3 variants in Dutch patients with Alzheimer's disease. ( 30314817 )
2019
27
TSPO and amyloid deposits in sub-regions of the hippocampus in the 3xTgAD mouse model of Alzheimer's disease. ( 30261283 )
2019
28
Cyclophilin D deficiency attenuates mitochondrial F1Fo ATP synthase dysfunction via OSCP in Alzheimer's disease. ( 30266287 )
2019
29
Protective roles of Amanita caesarea polysaccharides against Alzheimer's disease via Nrf2 pathway. ( 30290256 )
2019
30
Water-exchange MRI detects subtle blood-brain barrier breakdown in Alzheimer's disease rats. ( 30219292 )
2019
31
Low serum concentration of free triiodothyronine (FT3) is associated with increased risk of Alzheimer's disease. ( 30223192 )
2019
32
Association of the Polymorphisms and Plasma Level of CHI3L1 with Alzheimer's Disease in the Chinese Han Population: A Case-Control Study. ( 30223258 )
2019
33
Lewy body pathology in Alzheimer's disease: A clinicopathological prospective study. ( 30229861 )
2019
34
Exploring Alzheimer's disease mouse brain through X-ray phase contrast tomography: From the cell to the organ. ( 30240904 )
2019
35
Early intrathecal infusion of everolimus restores cognitive function and mood in a murine model of Alzheimer's disease. ( 30243986 )
2019
36
Effect of rivastigmine on plasma butyrylcholine esterase activity and plasma ghrelin levels in patients with dementia in Alzheimer's disease. ( 29441654 )
2018
37
Structural heterogeneity and intersubject variability of AI^ in familial and sporadic Alzheimer's disease. ( 29311311 )
2018
38
Alzheimer Disease Clinical Trial Recruitment: Does Participation in a Brief Cognitive Screen at a Community Health Fair Promote Research Engagement? ( 29944475 )
2018
39
Correction to: Comparison of the Effect of Exercise on Late-Phase LTP of the Dentate Gyrus and CA1 of Alzheimer's Disease Model. ( 28983832 )
2018
40
Strategic value-directed learning and memory in Alzheimer's disease and behavioural-variant frontotemporal dementia. ( 29431279 )
2018
41
Noncoding RNAs in Alzheimer's disease. ( 29327503 )
2018
42
The "glymphatic" mechanism for solute clearance in Alzheimer's disease: game changer or unproven speculation? ( 29101220 )
2018
43
Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms. ( 28943286 )
2018
44
Resveratrol attenuates oxidative damage through activating mitophagy in an in vitro model of Alzheimer's disease. ( 29097221 )
2018
45
Causal association between rheumatoid arthritis and aA decreased risk of Alzheimer's disease : AA Mendelian randomization study. ( 29974225 )
2018
46
Visual texture agnosia in dementia with Lewy bodies and Alzheimer's disease. ( 29673784 )
2018
47
Noncognitive Behavioral Changes Associated With Alzheimer's Disease: Implications of Neuroimaging Findings. ( 28876969 )
2018
48
Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease. ( 29254094 )
2018
49
Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention. ( 29170097 )
2018
50
Posterior Associative and Cingulate Cortex Involvement of Brain Single-Photon Emission Computed Tomography (SPECT) Imaging in Semantic Dementia with Probable Alzheimer Disease Pathology: A Case Report. ( 29429985 )
2018